Erlotinib-associated dermatological toxicity

Abstract

A 76-year-old, female, non-smoker developed all the spectrum of dermatological reactions 2 months after receiving erlotinib (150 mg daily) for advanced non-small cell lung cancer and known epidermal growth-factor receptor (EGFR) mutation. Her face had a papulopustular rash with erythematous and dry skin; trichomegaly (elongation and curling of the eyelashes), blepharitis and fine and brittle hair were also seen (Figure 1); finally, there was also periungual inflammation with …